Results 111 to 120 of about 883,722 (384)

Diversity in CD8+ T cell differentiation [PDF]

Current Opinion in Immunology, 2009
CD8(+) T cells are key effector cells of the adaptive immune system, however their activity must be tightly regulated to allow pathogen clearance whilst preventing immunopathology and autoimmunity. In this review, we summarise the diversity of responses that CD8(+) T cells make to antigenic stimulation with a focus on how CD8(+) T cell responses are ...
Parish, Ian, Kaech, Susan
openaire   +4 more sources

The significance of CD4+ and CD8+ T lymphocyte infiltration in esophageal squamous cell carcinoma

Indian Journal of Pathology and Microbiology
Purpose: To investigate the relationship between the abundance of CD4+ and CD8+ T cells in the tumor microenvironment and the prognosis of patients with esophageal squamous cell carcinoma, and to analyze their correlation and explore its clinical value ...
Jiang Y. Zhao, Xiaojun Pang, Jiao Peng, Jingtao Liu, Qiang Deng, Shunhai Jian   +5 more
doaj   +1 more source

Comparative analysis of immune activation markers of CD8+ T cells in lymph nodes of different origins in SIV-infected Chinese rhesus macaques

Frontiers in Immunology, 2016
Altered T-cell homeostasis, such as expansion of CD8+ T cells to the secondary lymphatic compartments has been suggested as a mechanism of HIV/SIV-pathogenesis.
Jinbiao Liu, Qianhao Xiao, Runhong Zhou, Yong Wang, Qianyang Xian, Tongcui Ma, Ke Zhuang, Li Zhou, Deyin Guo, Xu Wang, WENZHE HO, WENZHE HO, Jieliang Li   +12 more
doaj   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice [PDF]

, 2015
BACKGROUND: Ineffective induction of T cell mediated immunity in older individuals remains a persistent challenge for vaccine development. Thus, there is a need for more efficient and sophisticated adjuvants that will complement novel vaccine strategies ...
Amofah, E, Barber, LD, Farzaneh, F, Gaensler, KM, Harrison, PM, Ioannou, K, Krishnamurthy, P, Noble, A, Quartey-Papafio, R, Tye, GJ, Westrop, SJ   +10 more
core   +3 more sources

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. [PDF]

, 2017
HIV-specific CD8+ T cells demonstrate an exhausted phenotype associated with increased expression of inhibitory receptors, decreased functional capacity, and a skewed transcriptional profile, which are only partially restored by antiretroviral treatment (
Betts, Michael R, Buggert, Marcus, Deeks, Steven G, Frederiksen, Juliet, Hecht, Frederick M, Karlsson, Annika C, Ljunggren, Hans-Gustaf, Lund, Ole, Naji, Ali, Reyes-Terán, Gustavo, Scharf, Lydia, Sönnerborg, Anders, Tauriainen, Johanna   +12 more
core   +1 more source

KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans

Cell Reports, 2023
Summary: Subsets of the human CD8+ T cell population express inhibitory NK cell receptors, such as killer immunoglobulin-like receptors (KIRs) and NKG2A.
Seong Jin Choi, June-Young Koh, Min-Seok Rha, In-Ho Seo, Hoyoung Lee, Seongju Jeong, Su-Hyung Park, Eui-Cheol Shin   +7 more
doaj  

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

Frontiers in Immunology, 2018
Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 T cells by cross-presenting exogenous antigens, plays a critical role ...
Chunmei Fu, Aimin Jiang
semanticscholar   +1 more source